NASDAQ:IDYA IDEAYA Biosciences Q3 2024 Earnings Report $34.23 +3.00 (+9.61%) Closing price 04:00 PM EasternExtended Trading$33.58 -0.65 (-1.91%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast IDEAYA Biosciences EPS ResultsActual EPS-$0.60Consensus EPS -$0.63Beat/MissBeat by +$0.03One Year Ago EPS-$0.46IDEAYA Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$4.27 millionBeat/MissN/AYoY Revenue GrowthN/AIDEAYA Biosciences Announcement DetailsQuarterQ3 2024Date11/4/2024TimeBefore Market OpensConference Call DateMonday, November 4, 2024Conference Call Time6:00AM ETUpcoming EarningsIDEAYA Biosciences' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of DirectorsJune 17, 2026 | prnewswire.comHead to Head Survey: Trevi Therapeutics (NASDAQ:TRVI) versus IDEAYA Biosciences (NASDAQ:IDYA)June 17, 2026 | americanbankingnews.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year.June 22 at 1:00 AM | Paradigm Press (Ad)IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and ...June 15, 2026 | finance.yahoo.comIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung CancersJune 15, 2026 | prnewswire.comIDEAYA Biosciences (IDYA) Receives a Buy from GuggenheimJune 14, 2026 | theglobeandmail.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications. Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization. Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Buy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They?Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?3 Oil Refiners Built to Cash In on Higher Crack SpreadsSatellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
